COVID-19 trials registries data warehouse

https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-002447-22/SK

Pfizer Inc. - Clinical Trials.gov Call Centre

ClinicalTrials.gov_Inquiries@pfizer.com

2022-10-03

Completed

RCT

Randomized

Parallel

Blind label

multi-center

Treatment

1.Participants aged 12 years or older and weighing ≥40 kg at screening. -Refer to Appendix 4 for reproductive criteria and contraception requirements for male (Section 10.4.1) and female (Section 10.4.2) participants. 2. Meeting 1 of the 2 categories of COVID-19 risk: (see Appendix 9, Section 10.9.2). -Category A: Immunocompromised -Category B: Non-Immunocompromised, but with ≥2 risk factors -Onset of signs/symptoms attributable to COVID-19 ≤10 days prior to the day of randomization for non-immunocompromised participants (Category B). 3.Confirmed SARS-CoV-2 infection as determined by RT-PCR or acceptable test method performed by a health care provider (See Appendix 9, Section 10.9.3) in any specimen collected within 48 hours prior to randomization. 4.Hospitalized for inpatient care for the treatment of clinical manifestations of severe COVID-19 (see Appendix 9, Section 10.9.4). Requirement for oxygen supplementation (via nasal cannula, mask, NIV or high flow oxygen) to maintain SpO2 ≥94% at the time of Screening and Randomization. Participants with chronic lung disease requiring home oxygen therapy are eligible if they require a higher than usual oxygen flow rate to maintain their target oxygen saturation. 5.Requirement for oxygen supplementation (via nasal cannula, mask, NIV or high flow oxygen) to maintain SpO2 ≥94% at the time of Screening and Randomization. Participants with chronic lung disease requiring home oxygen therapy are eligible if they require a higher than usual oxygen flow rate to maintain their target oxygen saturation.

1.Critical illness, defined by ≥1 of the following: a.Requirement for mechanical ventilation or ECMO at randomization, or likely to require IMV or ECMO within 12 hours of randomization in the judgment of the investigator, or clinical need for mechanical ventilation or ECMO, even if not able to be administered due to resource limitation at the time of randomization. b.Multi-organ dysfunction/failure. c.Hemodynamically unstable, eg. septic shock, cardiac failure or requiring vasopressors. d.Participant not expected to survive 24 hours from time of randomization 2.History of severe chronic liver disease (see Appendix 9, Section 10.9.5). 3.Receiving dialysis of any kind or severe renal impairment defined as eGFR in adults <30 mL/min/1.73 m2 or eCrCl in adolescents aged 12 to 17 years <30 mL/min (see Section 10.7.1 for the recommended formulas). 4.Confirmed concurrent active systemic infection other than COVID-19 that may interfere with the evaluation of response to the study intervention. 5.History of hypersensitivity or other contraindication to any of the components of the study intervention, as determined by the investigator. 6.Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator’s judgment, make the patient inappropriate for the study. 7.Use of nirmatrelvir/ritonavir as an outpatient to treat the current COVID 19 related illness ≤7 days of randomization. 8.Current use of any prohibited concomitant medication(s). (See Section 6.9 and Appendix 8). 9.Inability to closely monitor concentrations of immunosuppressant medications (ie, Calcineurin inhibitors and mTOR inhibitors) and adjust their doses for nirmatrelvir/ritonavir DDI during active treatment, and for at least 5 days after the last dose of study intervention. 1.Previous administration with an investigational product (drug or vaccine-) within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer). 11.Known prior participation in this trial.

3

Pfizer Inc.

12

100

Argentina;Australia;Brazil;Bulgaria;Canada;France;Germany;Hungary;India;Mexico;Puerto Rico;Slovakia;Spain;United States

Severe disease at enrollment

6: Severe disease at enrollment

19

•Change from baseline in SARS CoV-2 RNA level in NP swabs at Day 5.

TODO

Phase 2

[{"arm_notes": "", "treatment_id": 1123, "treatment_name": "Ritonavir", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2497, "treatment_name": "Nirmatrelvir", "treatment_type": "Antivirals", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": null, "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]